Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Bonzano

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2022
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitisLuca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 28, 2022
The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registryAnnelie H Musters, Conor Broderick, David Prieto-Merino, et al.
Clinical and Molecular Allergy : CMA|December 21, 2021
Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholderEster Di Agosta, Lorenzo Salvati, Monica Corazza, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 29, 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort studyGianluca Avallone, Francesco Cavallo, Annalisa Tancredi, et al.
Dermatology and Therapy|October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort StudyGianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Clinical and Experimental Dermatology|July 9, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter StudyMaddalena Napolitano, Giuseppe Lauletta, Marianna Cimmino, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 7, 2025
<i>Letter:</i> Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World EvidenceFrancesca Barei, Paolo Calzari, Stefano Macchi, et al.
Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2022
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitisLuca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 28, 2022
The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registryAnnelie H Musters, Conor Broderick, David Prieto-Merino, et al.
Clinical and Molecular Allergy : CMA|December 21, 2021
Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholderEster Di Agosta, Lorenzo Salvati, Monica Corazza, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 29, 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort studyGianluca Avallone, Francesco Cavallo, Annalisa Tancredi, et al.
Dermatology and Therapy|October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort StudyGianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Clinical and Experimental Dermatology|July 9, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter StudyMaddalena Napolitano, Giuseppe Lauletta, Marianna Cimmino, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 7, 2025
<i>Letter:</i> Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World EvidenceFrancesca Barei, Paolo Calzari, Stefano Macchi, et al.
Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Pageof 10